Patient number . | Age at onset of symptoms (years) . | Age at time of diagnosis (years) . | Age at operation (years) . | Duration of disease (years) . | Gender . | Genetics . | MRI . |
---|---|---|---|---|---|---|---|
1 | 1 | 5 | 6 | 5 | Female | PKAN | Eye of the tiger |
2 | 1 | 6 | 9 | 8 | Male | PKAN | Eye of the tiger |
3 | 2 | 11 | 16 | 14 | Male | PKAN | Eye of the tiger |
4 | 2 | 5 | 12 | 10 | Female | Not tested | Eye of the tiger |
5 | 2 | 5 | 6 | 4 | Female | PKAN | Eye of the tiger |
6 | 2 | 5 | 9 | 7 | Female | Not tested | Eye of the tiger |
7 | 3 | 5 | 12 | 9 | Male | Not tested | Eye of the tiger |
8 | 4 | 8 | 14 | 10 | Male | PKAN | Eye of the tiger |
9a | 6 | 10 | 13 | 7 | Male | PKAN | Eye of the tiger |
10b | 8 | 10 | 17 | 9 | Male | PKAN | Eye of the tiger |
11c | 8 | 36 | 36 | 28 | Male | Not tested | Eye of the tiger |
12 | 9 | 11 | 13 | 4 | Male | PKAN | Eye of the tiger |
13 | 9 | 11 | 16 | 7 | Female | PKAN | Eye of the tiger |
14 | 9 | 13 | 17 | 8 | Male | PKAN | Eye of the tiger |
15 | 10 | 13 | 17 | 7 | Male | Not tested | Eye of the tiger |
16d | 11 | 13 | 29 | 18 | Female | Non-PKAN | Eye of the tiger |
17 | 12 | 16 | 32 | 20 | Female | PKAN | Eye of the tiger |
18 | 12 | 12 | 15 | 3 | Male | PKAN | Eye of the tiger |
19 | 12 | 13 | 24 | 12 | Female | PKAN | Eye of the tiger |
20 | 14 | 16 | 20 | 6 | Female | Not tested | Eye of the tiger |
21 | 14 | 33 | 36 | 22 | Male | PKAN | Eye of the tiger |
22 | 14 | 19 | 27 | 13 | Male | Not tested | Eye of the tiger |
23 | 15 | 15 | 19 | 4 | Male | Not tested | Eye of the tiger |
Mean ± SD | 7.8 ± 4.8 | 12.7 ± 8.0 | 18.0 ± 8.8 | 10.2 ± 6.4 | 10 females (43.5 %) 13 males (56.5 %) | 60.9% PKAN 4.3 % non-PKAN 34.8 % not tested |
Patient number . | Age at onset of symptoms (years) . | Age at time of diagnosis (years) . | Age at operation (years) . | Duration of disease (years) . | Gender . | Genetics . | MRI . |
---|---|---|---|---|---|---|---|
1 | 1 | 5 | 6 | 5 | Female | PKAN | Eye of the tiger |
2 | 1 | 6 | 9 | 8 | Male | PKAN | Eye of the tiger |
3 | 2 | 11 | 16 | 14 | Male | PKAN | Eye of the tiger |
4 | 2 | 5 | 12 | 10 | Female | Not tested | Eye of the tiger |
5 | 2 | 5 | 6 | 4 | Female | PKAN | Eye of the tiger |
6 | 2 | 5 | 9 | 7 | Female | Not tested | Eye of the tiger |
7 | 3 | 5 | 12 | 9 | Male | Not tested | Eye of the tiger |
8 | 4 | 8 | 14 | 10 | Male | PKAN | Eye of the tiger |
9a | 6 | 10 | 13 | 7 | Male | PKAN | Eye of the tiger |
10b | 8 | 10 | 17 | 9 | Male | PKAN | Eye of the tiger |
11c | 8 | 36 | 36 | 28 | Male | Not tested | Eye of the tiger |
12 | 9 | 11 | 13 | 4 | Male | PKAN | Eye of the tiger |
13 | 9 | 11 | 16 | 7 | Female | PKAN | Eye of the tiger |
14 | 9 | 13 | 17 | 8 | Male | PKAN | Eye of the tiger |
15 | 10 | 13 | 17 | 7 | Male | Not tested | Eye of the tiger |
16d | 11 | 13 | 29 | 18 | Female | Non-PKAN | Eye of the tiger |
17 | 12 | 16 | 32 | 20 | Female | PKAN | Eye of the tiger |
18 | 12 | 12 | 15 | 3 | Male | PKAN | Eye of the tiger |
19 | 12 | 13 | 24 | 12 | Female | PKAN | Eye of the tiger |
20 | 14 | 16 | 20 | 6 | Female | Not tested | Eye of the tiger |
21 | 14 | 33 | 36 | 22 | Male | PKAN | Eye of the tiger |
22 | 14 | 19 | 27 | 13 | Male | Not tested | Eye of the tiger |
23 | 15 | 15 | 19 | 4 | Male | Not tested | Eye of the tiger |
Mean ± SD | 7.8 ± 4.8 | 12.7 ± 8.0 | 18.0 ± 8.8 | 10.2 ± 6.4 | 10 females (43.5 %) 13 males (56.5 %) | 60.9% PKAN 4.3 % non-PKAN 34.8 % not tested |
PKAN = pantothenate kinase-associated neurodegeneration.
a Partially cited from Krause et al. (2006).
b Referred to in Shields et al. (2007).
c Cited from Umemura et al. (2004).
d Partially cited from Kurlemann et al. (1991).
Patient number . | Age at onset of symptoms (years) . | Age at time of diagnosis (years) . | Age at operation (years) . | Duration of disease (years) . | Gender . | Genetics . | MRI . |
---|---|---|---|---|---|---|---|
1 | 1 | 5 | 6 | 5 | Female | PKAN | Eye of the tiger |
2 | 1 | 6 | 9 | 8 | Male | PKAN | Eye of the tiger |
3 | 2 | 11 | 16 | 14 | Male | PKAN | Eye of the tiger |
4 | 2 | 5 | 12 | 10 | Female | Not tested | Eye of the tiger |
5 | 2 | 5 | 6 | 4 | Female | PKAN | Eye of the tiger |
6 | 2 | 5 | 9 | 7 | Female | Not tested | Eye of the tiger |
7 | 3 | 5 | 12 | 9 | Male | Not tested | Eye of the tiger |
8 | 4 | 8 | 14 | 10 | Male | PKAN | Eye of the tiger |
9a | 6 | 10 | 13 | 7 | Male | PKAN | Eye of the tiger |
10b | 8 | 10 | 17 | 9 | Male | PKAN | Eye of the tiger |
11c | 8 | 36 | 36 | 28 | Male | Not tested | Eye of the tiger |
12 | 9 | 11 | 13 | 4 | Male | PKAN | Eye of the tiger |
13 | 9 | 11 | 16 | 7 | Female | PKAN | Eye of the tiger |
14 | 9 | 13 | 17 | 8 | Male | PKAN | Eye of the tiger |
15 | 10 | 13 | 17 | 7 | Male | Not tested | Eye of the tiger |
16d | 11 | 13 | 29 | 18 | Female | Non-PKAN | Eye of the tiger |
17 | 12 | 16 | 32 | 20 | Female | PKAN | Eye of the tiger |
18 | 12 | 12 | 15 | 3 | Male | PKAN | Eye of the tiger |
19 | 12 | 13 | 24 | 12 | Female | PKAN | Eye of the tiger |
20 | 14 | 16 | 20 | 6 | Female | Not tested | Eye of the tiger |
21 | 14 | 33 | 36 | 22 | Male | PKAN | Eye of the tiger |
22 | 14 | 19 | 27 | 13 | Male | Not tested | Eye of the tiger |
23 | 15 | 15 | 19 | 4 | Male | Not tested | Eye of the tiger |
Mean ± SD | 7.8 ± 4.8 | 12.7 ± 8.0 | 18.0 ± 8.8 | 10.2 ± 6.4 | 10 females (43.5 %) 13 males (56.5 %) | 60.9% PKAN 4.3 % non-PKAN 34.8 % not tested |
Patient number . | Age at onset of symptoms (years) . | Age at time of diagnosis (years) . | Age at operation (years) . | Duration of disease (years) . | Gender . | Genetics . | MRI . |
---|---|---|---|---|---|---|---|
1 | 1 | 5 | 6 | 5 | Female | PKAN | Eye of the tiger |
2 | 1 | 6 | 9 | 8 | Male | PKAN | Eye of the tiger |
3 | 2 | 11 | 16 | 14 | Male | PKAN | Eye of the tiger |
4 | 2 | 5 | 12 | 10 | Female | Not tested | Eye of the tiger |
5 | 2 | 5 | 6 | 4 | Female | PKAN | Eye of the tiger |
6 | 2 | 5 | 9 | 7 | Female | Not tested | Eye of the tiger |
7 | 3 | 5 | 12 | 9 | Male | Not tested | Eye of the tiger |
8 | 4 | 8 | 14 | 10 | Male | PKAN | Eye of the tiger |
9a | 6 | 10 | 13 | 7 | Male | PKAN | Eye of the tiger |
10b | 8 | 10 | 17 | 9 | Male | PKAN | Eye of the tiger |
11c | 8 | 36 | 36 | 28 | Male | Not tested | Eye of the tiger |
12 | 9 | 11 | 13 | 4 | Male | PKAN | Eye of the tiger |
13 | 9 | 11 | 16 | 7 | Female | PKAN | Eye of the tiger |
14 | 9 | 13 | 17 | 8 | Male | PKAN | Eye of the tiger |
15 | 10 | 13 | 17 | 7 | Male | Not tested | Eye of the tiger |
16d | 11 | 13 | 29 | 18 | Female | Non-PKAN | Eye of the tiger |
17 | 12 | 16 | 32 | 20 | Female | PKAN | Eye of the tiger |
18 | 12 | 12 | 15 | 3 | Male | PKAN | Eye of the tiger |
19 | 12 | 13 | 24 | 12 | Female | PKAN | Eye of the tiger |
20 | 14 | 16 | 20 | 6 | Female | Not tested | Eye of the tiger |
21 | 14 | 33 | 36 | 22 | Male | PKAN | Eye of the tiger |
22 | 14 | 19 | 27 | 13 | Male | Not tested | Eye of the tiger |
23 | 15 | 15 | 19 | 4 | Male | Not tested | Eye of the tiger |
Mean ± SD | 7.8 ± 4.8 | 12.7 ± 8.0 | 18.0 ± 8.8 | 10.2 ± 6.4 | 10 females (43.5 %) 13 males (56.5 %) | 60.9% PKAN 4.3 % non-PKAN 34.8 % not tested |
PKAN = pantothenate kinase-associated neurodegeneration.
a Partially cited from Krause et al. (2006).
b Referred to in Shields et al. (2007).
c Cited from Umemura et al. (2004).
d Partially cited from Kurlemann et al. (1991).
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.